Holen Sie sich die Stockscreener-App
17.89
12.28%
-2.055
Schlusskurs vom Vortag:
$19.95
Offen:
$20.5001
24-Stunden-Volumen:
51,662
Relative Volume:
0.32
Marktkapitalisierung:
$38.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-563.30K
KGV:
-89.65
EPS:
-0.1996
Netto-Cashflow:
$-22.23M
1W Leistung:
-25.21%
1M Leistung:
+14.75%
6M Leistung:
+59.13%
1J Leistung:
-11.50%
1-Tages-Spanne:
$16.80
$21.02
1-Wochen-Bereich:
$16.80
$24.88
52-Wochen-Spanne:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
17.77 | 42.94M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.36 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.68 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.39 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.56 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.18 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
Sentiment Recap: Can ProMIS Neurosciences Inc. continue delivering strong returns2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Published on: 2026-03-10 05:13:34 - baoquankhu1.vn
Trade Report: Can ProMIS Neurosciences Inc continue delivering strong returnsJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc with Recent Share Purchase - GuruFocus
Published on: 2026-03-05 21:52:27 - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc - GuruFocus
Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat
Eugene Williams Acquires 1,000 Shares of Promis Neurosciences (NASDAQ:PMN) Stock - MarketBeat
ProMIS Neurosciences, Inc. (PMN.TO) Competitors - Meyka
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
ProMIS Neurosciences : PMN - 24/7 Wall St.
Ally Bridge entities disclose ProMIS (PMN) shares and warrant terms - Stock Titan
PMN PE Ratio & Valuation, Is PMN Overvalued - Intellectia AI
Can ADMA Biologics Inc deliver consistent EPS growthJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Insider Buying: Johanne Kaplan Acquires Shares of ProMIS Neurosc - GuruFocus
Insider buy: ProMIS Neurosciences (PMN) CDO acquires 1,629 shares at $15.35 - Stock Titan
Final Results - ADVFN
What to expect from Gossamer Bio’s late-stage lung disease study - statnews.com
ProMIS Neurosciences CEO touts “watershed year” as PMN310 Alzheimer’s Phase 1b data nears - Defense World
Is ProMIS Neurosciences Inc. stock positioned well for digital economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Promis Neurosciences (NASDAQ:PMN) Cut to “Strong Sell” at Wall Street Zen - Defense World
PMN Should I Buy - Intellectia AI
SPHERA FUNDS MANAGEMENT LTD. Acquires Additional Shares in ProMIS Neurosciences Inc. - GuruFocus
ProMIS Neurosciences: Phase 1b Alzheimer's trial fully enrolled and financed, with pivotal data expected in 2026 - TradingView
Is ProMIS Neurosciences Inc. (23J0) stock a safe buy pre earningsJobs Report & Weekly Breakout Stock Alerts - mfd.ru
Guggenheim Remains a Buy on ProMIS Neurosciences (PMN) - The Globe and Mail
Insider Stock Purchases: February 06, 2026 - Quiver Quantitative
ProMIS Neurosciences (PMN) Rating Maintained but Price Target Sl - GuruFocus
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profit Review: Can ProMIS Neurosciences Inc. continue delivering strong returnsJuly 2025 Trade Ideas & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Short Interest Down 14.8% in January - Defense World
ProMIS Neurosciences, Inc. announced that it expects to receive $75.464029 million in funding from a group of investors - marketscreener.com
ProMIS Neurosciences Announces $75 Million PIPE Financing - The Globe and Mail
ProMIS Neurosciences raises $175 million in PIPE financing By Investing.com - Investing.com South Africa
ProMIS Neurosciences Inc. (PMN) stock: surges 34% after $175M PIPE financing deal - parameter.io
ProMIS Neurosciences Secures $175 Mln In Private Financing - Nasdaq
ProMIS Neurosciences Stock Fluctuates Amid Market Developments - timothysykes.com
ProMIS Neurosciences Signs Multiple Material Agreements - TradingView
ProMIS Neurosciences raises $175 million in PIPE financing - Investing.com
ProMIS Neurosciences stock soars after $175 million private placement By Investing.com - Investing.com South Africa
ProMIS Neurosciences Secures $175 Million in PIPE Financing to Extend Cash Runway and Support Alzheimer’s Disease Clinical Study - Quiver Quantitative
ProMIS Neurosciences stock soars after $175 million private placement - Investing.com
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - The Manila Times
ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer’s trial - stocktitan.net
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):